Erin Burkhart
CIK: 0001927648
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (11 total)
- Sep 22, 2026GILD
GILEAD SCIENCES, INC.
Exercise(M)Direct2.2K shares- - Sep 22, 2026GILD
GILEAD SCIENCES, INC.
Tax Payment(F)Direct768 shares at avg. $152.67$117K - Mar 10, 2026GILD
GILEAD SCIENCES, INC.
Award(A)DirectNon-qualified Stock Option (Right to Buy)
5.5K shares- - Mar 10, 2026GILD
GILEAD SCIENCES, INC.
Award(A)DirectRestricted Stock Unit
2.4K shares- - Sep 22, 2025GILD
GILEAD SCIENCES, INC.
Award(A)DirectRestricted Stock Unit
8.9K shares- - May 20, 2025BMRN
BIOMARIN PHARMACEUTICAL INC
Sale(S)Direct1.8K shares at avg. $59.31$106K - May 19, 2025BMRN
BIOMARIN PHARMACEUTICAL INC
Tax Payment(F)Direct996 shares at avg. $59.27$59K - Mar 19, 2025BMRN
BIOMARIN PHARMACEUTICAL INC
Sale(S)Direct1.3K shares at avg. $71.52$93K - Mar 17, 2025BMRN
BIOMARIN PHARMACEUTICAL INC
Award(A)Direct6K shares- - Mar 14, 2025BMRN
BIOMARIN PHARMACEUTICAL INC
Tax Payment(F)Direct823 shares at avg. $69.44$57K - Feb 24, 2025BMRN
BIOMARIN PHARMACEUTICAL INC
Sale(S)Direct1.3K shares at avg. $68.38$92K
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Sep 22, 2026 |  GILD GILEAD SCIENCES, INC. | Exercise(M) | 2,223 | - | $0 | Direct |
| Sep 22, 2026 | GILD GILEAD SCIENCES, INC. | Tax Payment(F) | 768 | $152.67 | $117,251 | Direct |
| Mar 10, 2026 | GILD GILEAD SCIENCES, INC. | Award(A) Non-qualified Stock Option (Right to Buy) | 5,455 | - | - | Direct |
| Mar 10, 2026 | GILD GILEAD SCIENCES, INC. | Award(A) Restricted Stock Unit | 2,355 | - | - | Direct |
| Sep 22, 2025 | GILD GILEAD SCIENCES, INC. | Award(A) Restricted Stock Unit | 8,890 | - | - | Direct |
| May 20, 2025 |  BMRN BIOMARIN PHARMACEUTICAL INC | Sale(S) | 1,786 | $59.31 | $105,928 | Direct |
| May 19, 2025 | BMRN BIOMARIN PHARMACEUTICAL INC | Tax Payment(F) | 996 | $59.27 | $59,033 | Direct |
| Mar 19, 2025 | BMRN BIOMARIN PHARMACEUTICAL INC | Sale(S) | 1,295 | $71.52 | $92,618 | Direct |
| Mar 17, 2025 | BMRN BIOMARIN PHARMACEUTICAL INC | Award(A) | 5,970 | - | - | Direct |
| Mar 14, 2025 | BMRN BIOMARIN PHARMACEUTICAL INC | Tax Payment(F) | 823 | $69.44 | $57,149 | Direct |
| Feb 24, 2025 | BMRN BIOMARIN PHARMACEUTICAL INC | Sale(S) | 1,344 | $68.38 | $91,903 | Direct |
1-11 of 11 transactions
About Burkhart Erin
Burkhart Erin (SEC CIK 0001927648) files insider reports with the SEC as SVP, Controllership of GILEAD SCIENCES, INC. (GILD) and GVP, Chief Accounting Officer of BIOMARIN PHARMACEUTICAL INC (BMRN).
Signal8 holds 8 ownership filings by Burkhart Erin (1 Form 3, 7 Form 4), filed between Feb 25, 2025 and Sep 23, 2026. Those filings report 11 transactions, from Feb 24, 2025 to Sep 22, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Burkhart Erin's filings is in FOSTER CITY, CA.
Recent filings by Burkhart Erin
- Sep 22, 2026: Option exercise of GILD shares (Form 4, code M).
- Sep 22, 2026: Tax withholding of GILD shares (Form 4, code F).
- Mar 10, 2026: Grants or awards of GILD derivative securities (2 lines, Form 4, code A).
- Sep 22, 2025: Grant or award of GILD derivative securities (Form 4, code A).
- May 20, 2025: Open-market sale of BMRN shares (Form 4, code S).
Other insiders filing for GILEAD SCIENCES, INC. (GILD)
- O'Day Daniel Patrick, Chairman & CEO
- Dickinson Andrew D, Chief Financial Officer
- Mercier Johanna, Chief Comm & Corp Aff Officer
- Berger Dietmar, Chief Medical Officer
- Cain Wettan Keeley M, EVP Gen Counsel, Legal & Comp
- WELTERS ANTHONY, Director